1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Neoplastic Syndrome Global Clinical Trials Review, H1, 2014

Neoplastic Syndrome Global Clinical Trials Review, H1, 2014

Summary

GlobalData's clinical trial report, “Neoplastic Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Neoplastic Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neoplastic Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neoplastic Syndrome. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table Of Contents

Neoplastic Syndrome Global Clinical Trials Review, H1, 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Neoplastic Syndrome 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Clinical Trials by G7 Countries: Proportion of Neoplastic Syndrome to Oncology Clinical Trials 12
Clinical Trials by Phase in G7 Countries 13
Clinical Trials in G7 Countries by Trial Status 14
Clinical Trials by E7 Countries: Proportion of Neoplastic Syndrome to Oncology Clinical Trials 15
Clinical Trials by Phase 16
In Progress Trials by Phase 17
Clinical Trials by Trial Status 18
Clinical Trials by End Point Status 19
Subjects Recruited Over a Period of Time 20
Clinical Trials by Sponsor Type 21
Prominent Sponsors 22
Top Companies Participating in Neoplastic Syndrome Therapeutics Clinical Trials 23
Prominent Drugs 24
Clinical Trial Profiles 25
Clinical Trial Overview of Top Companies 25
Novartis AG 25
Clinical Trial Overview of Novartis AG 25
Johnson and Johnson 26
Clinical Trial Overview of Johnson and Johnson 26
Clinical Trial Overview of Top Institutes / Government 27
National Cancer Institute 27
Clinical Trial Overview of National Cancer Institute 27
Memorial Sloan Kettering Cancer Center 28
Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 28
Rockefeller University 29
Clinical Trial Overview of Rockefeller University 29
University of California, San Francisco 30
Clinical Trial Overview of University of California, San Francisco 30
Federation Francophone de Cancerologie Digestive 31
Clinical Trial Overview of Federation Francophone de Cancerologie Digestive 31
Erasmus MC 32
Clinical Trial Overview of Erasmus MC 32
Yale University 33
Clinical Trial Overview of Yale University 33
Mount Sinai Medical Center 34
Clinical Trial Overview of Mount Sinai Medical Center 34
Eunice Kennedy Shriver National Institute of Child Health and Human Development 35
Clinical Trial Overview of Eunice Kennedy Shriver National Institute of Child Health and Human Development 35
Eastern Cooperative Oncology Group 36
Clinical Trial Overview of Eastern Cooperative Oncology Group 36
Five Key Clinical Profiles 37
Appendix 113
Abbreviations 113
Definitions 113
Research Methodology 114
Secondary Research 114
About GlobalData 115
Contact Us 115
Disclaimer 115
Source 116

List of Tables
Neoplastic Syndrome Therapeutics, Global, Clinical Trials by Region, 2014* 6
Neoplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Neoplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Neoplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014* 9
Neoplastic Syndrome Therapeutics Clinical Trials, Europe, Top Countries, 2014* 10
Neoplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2014* 11
Proportion of Neoplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Neoplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Neoplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Proportion of Neoplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2014* 15
Neoplastic Syndrome Therapeutics, Global, Clinical Trials by Phase, 2014* 16
Neoplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 17
Neoplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Neoplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2014* 19
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Neoplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 21
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 22
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 23
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 24
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014* 25
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson and Johnson, 2014* 26
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014* 27
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014* 28
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Rockefeller University, 2014* 29
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by University of California, San Francisco, 2014* 30
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Federation Francophone de Cancerologie Digestive, 2014* 31
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Erasmus MC, 2014* 32
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 33
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Mount Sinai Medical Center, 2014* 34
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Eunice Kennedy Shriver National Institute of Child Health and Human Development, 2014* 35
Neoplastic Syndrome Therapeutics Clinical Trials Market, Global, Clinical Trials by Eastern Cooperative Oncology Group, 2014* 36

List of Figures
Neoplastic Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Neoplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Neoplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 8
Neoplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014* 9
Neoplastic Syndrome Therapeutics Clinical Trials, Europe, Top Countries (%), 2014* 10
Proportion of Neoplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2014* 12
Neoplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 13
Neoplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 14
Proportion of Neoplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2014* 15
Neoplastic Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2014* 16
Neoplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 17
Neoplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2014* 18
Neoplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2014* 19
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 20
Neoplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 21
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2014* 22
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014* 23
Neoplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 24
GlobalData Methodology 114

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • August 2016
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2025 Summary Cardiovascular diseases (CVD), including ischemic heart disease and stroke, are the leading causes of mortality ...

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.